A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)

The main purpose of this study is to evaluate the efficacy of bemarituzumab (FPA144), which
is a targeted antibody, in combination with modified FOLFOX6 compared to placebo in
combination with modified FOLFOX6 in participants with Gastric Cancer as measured by overall
survival.

Key Inclusion Criteria:

- Histologically documented gastric or gastroesophageal junctional adenocarcinoma (not
amenable to curative therapy)

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

- Adequate hematological, liver and kidney function. Measurable or non-measurable, but
evaluable disease using RECIST v1.1

- FGFR2b overexpression as determined by a centrally performed IHC tissue test and/or
FGFR2 gene amplification as determined by a centrally performed ctDNA blood based
assay

- Candidate for mFOLFOX6 chemotherapy

Key Exclusion Criteria:

- Untreated or symptomatic central nervous system (CNS) metastases

- Clinically significant cardiac disease,

- Peripheral sensory neuropathy >/= Common Terminology Criteria for Adverse Events
(CTCAE) Grade 2

- Active infection requiring systemic treatment

- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
(AIDS)-related illness, or known active or chronic hepatitis B or C infection

- Prior treatment with any selective inhibitor of the fibroblast growth factor
(FGF)-FGFR pathway

- Known abnormalities of the cornea that may pose an increased risk of developing a
corneal ulcer

- Known positivity for HER2

- Women who are pregnant or breastfeeding

Note: Other protocol defined Inclusion/Exclusion criteria may apply